Optical Drug Response Profiling for Personalized Cancer Cell Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for testing drug efficacy on cancer cells are not personalized to individual patients, relying on population-based guidelines that may not account for genetic variations and patient-specific factors, leading to suboptimal treatment outcomes.
Innovation Solution
An optical density and fluorescent measurement system that isolates live cancer cells from patient samples, administers drug treatments with varying dosages, and uses high-resolution imaging and flow cytometry to assess immune markers, generating personalized treatment recommendations through AI-assisted analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If population-based treatment guidelines are used, then treatment can be standardized and easily implemented, but treatment outcomes may be suboptimal due to lack of personalization for individual genetic variations
Solution Approach 1:
The invention segments the patient population into individual cases by performing personalized drug sensitivity testing on each patient's cancer cells. Instead of applying a uniform population-based approach, the system divides treatment decisions into patient-specific evaluations using optical density measurement and flow cytometry to determine individual drug responses, thereby resolving the contradiction between standardization ease and personalized efficacy.
2Reliability
If personalized drug sensitivity testing is performed on each patient's cancer cells, then treatment efficacy is optimized for individual patients, but the complexity and time required for testing increases
Solution Approach 1:
The invention employs a multi-functional integrated system that combines optical density measurement, flow cytometry analysis, and drug sensitivity testing into a single platform. This universal system can perform multiple functions (cell counting, viability assessment, drug response evaluation) simultaneously, reducing the overall complexity compared to using separate specialized devices for each measurement type.
Solution Approach 2:
The system utilizes changes in optical density parameters and flow cytometry measurements to assess drug sensitivity. By monitoring parameter changes (optical density at different wavelengths, fluorescent intensity) in response to drug treatment, the system simplifies the testing process while maintaining high reliability in determining personalized treatment efficacy.
3Measurement precision
If multiple measurement parameters (optical density, flow cytometry, fluorescent intensity) are measured simultaneously, then comprehensive drug response evaluation is achieved, but the data analysis complexity and processing time increases
Solution Approach 1:
The system performs preliminary data processing by establishing baseline optical density and flow cytometry measurements before drug treatment. By pre-characterizing the cancer cells and setting reference parameters in advance, the system reduces the complexity of post-treatment analysis and accelerates the overall evaluation process while maintaining comprehensive measurement precision.
Solution Approach 2:
The invention implements a feedback mechanism where optical density measurements and flow cytometry data are continuously monitored during drug treatment. The system uses real-time feedback from these measurements to adjust and optimize the evaluation process, reducing unnecessary processing steps and minimizing data analysis time while maintaining accurate drug response assessment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise evaluation of drug responses tailored to individual patients, balancing efficacy and tolerability by integrating genetic markers, drug resistances, and immune system activation profiles, thereby optimizing chemotherapy and immunotherapy.
Implementation Method 1
an optical density measurement device equipped with a high-resolution optical sensor captures sequential images of the cancer cells at predetermined intervals, thereby enabling quantification of live cell populations over time
Implementation Method 2
An optical spectrophotometric reader is coupled to the optical density measurement device to measure concentration and growth of the live cells following drug administration
Implementation Method 3
A flow cytometry subsystem is further integrated to measure fluorescent intensities of immune checkpoint markers and tumor antigens, including PD-1, PD-L1, and CTLA-4, expressed in the cancer cells
Data Source
AI summary
The embodiment discloses an optical density measurement and testing including a purification device that separates live cancer cells from dead and non-cancer cells of a microbiology sample. A drug addition device and a drug dosage sequencer introduce controlled dosages of at least one drug treatment into the live cancer cells. An optical density measurement device with an optical sensor captures high-resolution images of the live cells at predetermined intervals, and an optical spectrophotometric reader quantifies cell populations following treatment. A flow cytometry device measures fluorescent intensities of immune checkpoint markers and tumor antigens to generate immune system activation profiles. A processor subsystem analyzes cell death rates and immune responses to create integrated drug response profiles, and a computer application compares these results with patient-specific genetic and clinical data to produce personalized treatment recommendations.